Misfit Unveils Speedo Shine 2, Will Enable Lap Counting For All Shine 2 and Ray Devices
Misfit and Speedo today announced the launch of their second Speedo-branded activity, swim, and sleep tracker, Misfit Shine 2 Swimmer’s Edition, powered by Speedo, known as Speedo Shine 2. The result of Misfit and Speedo’s long-term partnership, Speedo Shine 2 is available now on misfit.com, SpeedoUSA.com, and Speedo.com for $119.99.
“Whether you’re training competitively or swimming for fitness, you want your focus to be on speed and form – not tracking laps. With the Speedo Shine 2, you can concentrate on your efforts in the pool without distractions,” said Team Speedo USA athlete and four-time Olympic medalist Cullen Jones. “Speedo Shine 2 is an ideal aid for athletes and fitness enthusiasts to maximize their time in the water while keeping track of their overall fitness and sleep.”
Speedo Shine 2 is the next generation of Speedo Shine, the first device of its kind designed with swimmers in mind. Misfit and Speedo’s proprietary lap counting algorithms track a swimmer’s lap count with industry-leading accuracy and work for all stroke types. New features with Speedo Shine 2 include:
- A vibration motor and multicolor lights, enabling multi-faceted user feedback — see progress and tell time in a halo of rainbow-colored lights, or get motivated with Misfit Move activity reminders;
- A countdown swim timer — users pick a time to swim and Speedo Shine 2 provides a gentle vibe alert when a workout is complete;
- Text and call notifications and a silent vibe alarm;
- Misfit Link compatibility, turning Speedo Shine 2 into a music remote, selfie trigger, presentation clicker, or button to enable a variety of smart home devices and web services
Speedo Shine 2 features Misfit’s most advanced hardware and firmware, which offers dramatically improved touch responsiveness with capacitive touch technology, faster syncing, and an extended Bluetooth range. Its 12 lights display over 16 million colors and are bright enough to be seen in direct sunlight.
Additionally, Misfit will enable all Misfit Ray and Misfit Shine 2 devices with Speedo and Misfit’s world-class swim tracking and lap counting technology via an in app-purchase of $9.99. With this and future updates, Misfit users can customize and enhance their app experience based on the activities and features that matter most to them.
About Speedo Shine 2
Speedo Shine 2 is the next generation of Speedo Shine, the first device of its kind designed with swimmers in mind. Proprietary lap counting algorithms embedded in the device’s firmware track a swimmer’s lap count with industry-leading accuracy and work for all stroke types. Crafted from clear anodized aircraft-grade aluminum, Speedo Shine 2 is water resistant to 50 meters. Even thinner than its predecessor, Speedo Shine 2 is meant to be worn both in and out of the water, and also tracks walking, running, cycling, and light and deep sleep. Speedo Shine 2 never requires charging, using a coin-cell battery to power the device for up to 6 months. Speedo Shine 2 syncs with the Misfit app for iOS and Android and displays laps and swim distance, along with calories burned and points earned. Compatible with Misfit Link, the groundbreaking software experience, Speedo Shine 2 is more than just an activity tracker — it’s now a remote to connect with the world around you. Communicate with friends, turn your lights on, change your music, take a selfie, and more, all with a triple tap. The also device works with Speedo’s personalized swim tracking app, Speedo Fit, to provide a fine-grain resolution into your swim fitness.
The world’s leading swimwear brand, Speedo is passionate about life in and around the water, creating revolutionary new technologies, designs and innovations and supporting swimming from grass-roots through to elite level. In the 1920s Speedo made history with the Racerback: the world’s first non-wool suit. In 2008 Speedo redefined swimwear again with Fastskin LZR RACER - the fastest and most technologically advanced swimsuit ever created. In 2015, Speedo launched the Fastskin LZR Racer X, the first suit engineered to help swimmers feel their fastest. Its development was made possible through analyses of the physical and psychological aspects of competitive swimming with over 330 elite swimmers, including multiple world-record holder Ryan Lochte. Speedo is owned by Speedo Holdings B.V and distributed in over 170 countries around the world. SPEEDO, the ARROW device, FASTSKIN, AQUALAB, RACING SYSTEM, BIOFUSE, SPEEDO ENDURANCE, SCULPTURE and LZR RACER are registered trademarks of Speedo Holdings B.V. The LZR RACER suit has worldwide design rights and patents. The FASTSKIN cap, goggle and suit has worldwide design rights and patents pending. To find out more visit: www.speedo.com
Misfit invents and designs wearables and smart home products. Misfit brand products including Ray, Shine 2, Flash, Link, and Bolt are available at misfit.com and fashion and consumer electronic retailers around the world. To learn more about Misfit, a Fossil Group (NASDAQ: FOSL) brand, visit http://misfit.com/media.
Copyright 2016 Misfit, Inc. All rights reserved.
Amy Puliafito, +1 415-868-5249
Christine Thomas, 212-704-4505
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease18.7.2018 21:45 | Pressemelding
VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings showed lower cumulative days in hospital of 41 percent; p=0.02 (median 6.5 days vs. median 11 days) and a lower incidence of acute chest syndrome (ACS) by more than 60 percent; p=0.003 (13 of 152 patients [8.6%] had at least 1 ACS compared with 18 of 78 in the placebo group [23.1%]). The most common adverse reactions, occurring in great
Tigo Releases State-of-the-art Wireless Technology – Mesh – as the New Solar Communication Architecture for the TS4 Platform18.7.2018 19:41 | Pressemelding
Tigo®, pioneer of the smart modular Flex MLPE platform, today announced the release of its new Mesh communication architecture. This state-of-the-art wireless technology directly translates to customer benefits – including simplifying the solar design process and accelerating the commissioning steps. The complete Tigo solution uses a simple yet powerful data collection technology that covers the widest ranges of residential & commercial installations at the lowest cost. With Mesh and the recently announced Tigo Access Point (TAP), customers eliminate the need to address any roof obstruction or orientation constraint. To learn more about Mesh and TAP, register for Tigo’s free, online webinar “The Future of Solar is Wireless” on Wednesday July 25th, 2018 at 10am PDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180718005827/en/ Mesh is Tigo's proprietary software that allows each TS4 unit to act as a repeater, extending the
ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 201818.7.2018 17:21 | Pressemelding
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with li
Xilam: H1 2018 Revenue: +50%18.7.2018 16:00 | Pressemelding
Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2018 revenue of EUR 13,866 thousand, an increase of 50%. This increase represents an excellent performance, as it follows on the heels of growth of 54% in H1 2017. Revenue for the first part of this financial year breaks down as follows. In thousands of euros 30.06.2018 (1) 30.06.2017 Change New productions 8,465 4,571 +85% Catalogue 5,385 4,652 +16% Other 16 16 +0% Revenue and subsidies 13,866 9,239 +50% (1) Unaudited data. Remarkable success for new releases +85% Excellent H1 growth was driven by the two main businesses, New Productions and Catalogue. In New Productions, H1 deliveries generated record revenue of EUR 8,465 thousand, an 85% increase compared with H1 2017, and confirmed Xilam’s position as a major European animation company. Catalogue revenue was up 16% compared with H1 2017, thanks again to traditional TV channels and digital platforms, in both France and abroad. A fast-paced delivery schedule Thanks t
Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38 | Pressemelding
The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign
Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05 | Pressemelding
Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d